下一代癌症診斷市場－全球產業規模、佔有率、趨勢、機會及預測（按技術、應用、癌症類型、地區和競爭格局分類，2021-2031年）

全球新一代癌症診斷市場預計將從 2025 年的 160.2 億美元成長到 2031 年的 258.9 億美元，複合年成長率為 8.33%。

這些先進的診斷系統利用先進的基因組學和蛋白​​質組學技術，包括高通量定序和液態生物檢體，來檢測對腫瘤患者管理至關重要的特定生物標記。推動市場擴張的關鍵因素是全球惡性腫瘤負擔日益加重，這促使人們需要早期、準確的檢測方法來支持個人化治療策略。美國癌症協會的數據凸顯了這種緊迫性，該協會估計，到2024年，美國將新增約2,001,140例癌症病例，這凸顯了對可擴展診斷解決方案的迫切需求，這些解決方案能夠推進精準腫瘤學的發展並改善患者預後。

儘管臨床獲益顯而易見，但市場仍面臨許多挑戰，包括定序基礎設施所需的大量資本投入以及高昂的檢測營運成本。這些財務挑戰限制了這些技術在成本敏感地區的廣泛應用，而複雜的報銷政策更令醫療服務提供者不確定性，加劇了這些挑戰。因此，這些經濟和監管方面的挑戰使得新型診斷檢測難以整合到標準治療通訊協定中，限制了其應用，儘管這些檢測具有提升癌症治療水平的潛力。

市場促進因素

次世代定序和液態生物檢體技術的進步正在從根本上改變癌症診斷領域，實現高通量、非侵入性的腫瘤分析。特別是液態生物檢體技術的創新，能夠精準識別循環腫瘤DNA，為早期檢測和持續病患監測提供了一種切實可行的替代方案，取代了傳統的組織切片檢查。這些技術的商業性成功體現在主要產業參與者不斷成長的檢測量上。例如，Guardant Health在2025年2月的財務報告中宣布，其年收入成長31%至7.39億美元，主要得益於臨床腫瘤檢測量成長20%。同樣，Exact Sciences在其2025年2月的報告中宣布，其2024年全年總收入為27.6億美元，這表明市場對先進的篩檢和診斷工具的需求強勁。

此外，基因組定序成本的下降是推動更廣泛患者群體獲得先進診斷技術的關鍵因素。儘管高成本歷來限制了基因組分析的臨床應用，但定序化學和平台效率的持續改進正在顯著降低每GB數據的成本。如同2025年3月《前沿基因組學》（Front Line Genomics）雜誌的一篇報導所述，Illumina公司已證明，其最新平台可望將全基因組定序的成本降低至200美元。經濟門檻的降低至關重要，它使醫療機構能夠將全面的基因組分析納入常規標準診療通訊協定，並加速精準腫瘤學在全球的普及。

市場挑戰

建構定序基礎設施所需的大量資本投入，加上高昂的檢測營運成本，是限制全球下一代癌症診斷市場成長的主要障礙。這些資金需求限制了先進基因組技術的應用，使其主要局限於資金雄厚的醫療中心，實際上將小規模的醫療機構和經濟低度開發地區排除在市場之外。這種經濟上的排他性阻礙了可擴展診斷解決方案的廣泛部署，縮小了潛在基本客群，並抑制了整體市場規模的成長。

此外，這些檢測的高昂費用對患者和支付方都造成了沉重的經濟負擔，使報銷流程複雜化，也難以將其納入標準治療方案。近期關於癌症治療經濟負擔的統計數據也印證了這一經濟負擔：在2024年美國臨床腫瘤學會（ASCO）年會上發表的一項分析顯示，確診癌症後六個月內，擁有私人保險的在職成年人的醫療總費用中位數為60,123美元。如此高昂的費用使得醫療系統難以將這些昂貴的診斷工具標準化，直接影響了市場滿足全球日益成長的精準癌症治療需求的能力。

市場趨勢

人工智慧 (AI) 與精準分析的融合正在革新全球新一代癌症診斷市場，協助解讀日益複雜的生物數據。隨著診斷檢測從單一生物標記檢測發展到多模態態分析，人工智慧在關聯基因組變異與臨床結果以及識別傳統方法往往忽略的細微預測特徵方面變得至關重要。這種技術融合正在推動商業性成長，Tempus AI 截至 2025 年 2 月的會計年度業績（營收 6.934 億美元，年成長 30.4%）就印證了這一點。這一快速成長主要歸功於該公司人工智慧驅動的精準醫療和數據解決方案的可擴展部署。

同時，伴隨診斷聯合開發夥伴關係的拓展正在加強診斷檢測與標靶治療選擇之間的關聯。製藥公司和診斷設備製造商正日益建立策略聯盟，共同開發新型藥物的配套檢測，尤其是在免疫腫瘤學和抗體藥物複合體（ADC）領域，從而確保在診療現場對患者合格進行高度精準的判斷。此類合作對於降低藥物研發風險、加速監管核准至關重要，並為診斷設備領導企業創造永續的收入來源。例如，安捷倫科技公司公佈其診斷和基因組學部門2024年11月的年收入為16.5億美元，凸顯了儘管面臨行業整體的挑戰，市場對其病理診斷和伴隨診斷產品組合的持續需求。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章：全球下一代癌症診斷市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 透過技術（次世代定序、qPCR 和多重 PCR、實驗室晶片(LOAC) 和逆轉錄聚合酵素鏈鎖反應(RT-PCR)、蛋白質微陣列、DNA 微陣列）
  • 依應用領域分類（生物標記開發、循環腫瘤細胞分析、蛋白質體學分析、表觀遺傳學分析、基因分析）
  • 癌症類型（肺癌、乳癌、結腸癌、子宮頸癌、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美下一代癌症診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲下一代癌症診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區下一代癌症診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲下一代癌症診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲下一代癌症診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章：全球下一代癌症診斷市場：SWOT分析

第14章 波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• GE HealthCare
• Janssen Pharmaceuticals, Inc.
• Illumina, Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Koninklijke Philips NV
• QIAGEN
• Agilent Technologies, Inc.
• Abbott Laboratories Inc.
• Thermo Fisher Scientific Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Next Generation Cancer Diagnostics Market is projected to expand from USD 16.02 Billion in 2025 to USD 25.89 Billion by 2031, registering a CAGR of 8.33%. These advanced diagnostic systems leverage sophisticated genomic and proteomic technologies, including high-throughput sequencing and liquid biopsies, to detect specific biomarkers essential for patient management in oncology. The primary catalyst for this market expansion is the escalating global burden of malignancies, which drives the need for early and precise detection methods to support personalized treatment strategies. This urgency is highlighted by data from the American Cancer Society, which estimated approximately 2,001,140 new cancer cases in the United States in 2024, reinforcing the critical demand for scalable diagnostic solutions that facilitate precision oncology and enhance patient outcomes.

Despite the evident clinical benefits, the market encounters significant obstacles regarding the heavy capital investment needed for sequencing infrastructure and the elevated operational costs of test execution. These financial hurdles restrict the widespread adoption of these technologies in cost-sensitive regions and are frequently exacerbated by complicated reimbursement policies that introduce uncertainty for healthcare providers. Consequently, these economic and regulatory barriers make it challenging to integrate novel diagnostic assays into standard care protocols, limiting their accessibility despite their potential to improve cancer care standards.

Market Driver

Technological advancements in next-generation sequencing and liquid biopsy are fundamentally transforming the cancer diagnostics sector by facilitating high-throughput, non-invasive tumor profiling. In particular, innovations in liquid biopsy allow for the accurate identification of circulating tumor DNA, providing a practical alternative to conventional tissue biopsies for early detection and ongoing patient monitoring. The commercial success of these technologies is reflected in the rising test volumes of major industry players; for instance, Guardant Health reported a 31% increase in full-year revenue to $739 million in its February 2025 financial results, driven largely by a 20% rise in clinical oncology test volumes. Similarly, Exact Sciences announced total revenue of $2.76 billion for the full year 2024 in its February 2025 report, demonstrating the robust market demand for advanced screening and diagnostic tools.

Additionally, the declining cost of genomic sequencing is acting as a vital catalyst for democratizing access to these advanced diagnostic capabilities across a wider patient population. Although high costs have historically limited the clinical implementation of genomic profiling, continuous improvements in sequencing chemistry and platform efficiency are significantly lowering the cost per gigabyte of data. As noted in a March 2025 article by Front Line Genomics, Illumina indicated that its latest platforms could potentially lower the cost of whole genome sequencing to $200. This reduction in financial barriers is crucial, as it enables healthcare providers to incorporate comprehensive genomic profiling into routine standard-of-care protocols, thereby accelerating the global adoption of precision oncology.

Market Challenge

The substantial capital investment necessary to establish sequencing infrastructure, combined with the high operational costs of test execution, poses a major barrier to the growth of the Global Next Generation Cancer Diagnostics Market. These financial demands limit the adoption of advanced genomic technologies primarily to well-funded medical centers, effectively excluding smaller healthcare facilities and economically constrained regions from participating in the market. This economic exclusivity hampers the broad deployment of scalable diagnostic solutions, narrowing the potential customer base and stalling the overall growth of market volume.

Moreover, the high price of these assays creates significant financial toxicity for both patients and payers, complicating the processes of reimbursement and integration into standard care. This financial strain is underscored by recent statistics on the economic burden of cancer treatment; an analysis presented at the 2024 American Society of Clinical Oncology annual meeting revealed that median total healthcare spending for working-age adults with private insurance was $60,123 in the six months following a diagnosis. Such prohibitive costs discourage healthcare systems from standardizing these expensive diagnostic tools, directly affecting the market's ability to satisfy the rising global demand for precision oncology.

Market Trends

The integration of artificial intelligence into precision analytics is revolutionizing the Global Next Generation Cancer Diagnostics Market by facilitating the interpretation of increasingly complex biological data. As diagnostic assays evolve from single-biomarker detection to multimodal profiling, AI is becoming indispensable for correlating genomic alterations with clinical outcomes and identifying subtle predictive signatures that traditional methods might miss. This convergence of technologies is driving commercial growth, as evidenced by Tempus AI, which reported a 30.4% year-over-year revenue increase to $693.4 million in its February 2025 financial results, a surge attributed largely to the scalable adoption of its AI-enabled precision medicine and data solutions.

Concurrently, the expansion of companion diagnostics co-development partnerships is strengthening the link between diagnostic testing and targeted therapeutic selection. Pharmaceutical and diagnostic companies are increasingly forming strategic alliances to develop assays alongside novel drugs, particularly for immuno-oncology and antibody-drug conjugates, ensuring that patient eligibility is determined with high specificity at the point of care. These collaborations are crucial for mitigating drug development risks and accelerating regulatory approvals, thereby creating resilient revenue streams for diagnostic leaders. For example, Agilent Technologies reported in November 2024 that its Diagnostics and Genomics Group generated $1.65 billion in annual revenue, highlighting the sustained market demand for its pathology and companion diagnostic portfolio despite broader industry headwinds.

Key Market Players

• GE HealthCare
• Janssen Pharmaceuticals, Inc.
• Illumina, Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Koninklijke Philips N.V.
• QIAGEN
• Agilent Technologies, Inc.
• Abbott Laboratories Inc.
• Thermo Fisher Scientific Inc

Report Scope

In this report, the Global Next Generation Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Next Generation Cancer Diagnostics Market, By Technology

• Next-generation Sequencing
• qPCR & Multiplexing
• Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
• Protein Microarrays
• DNA Microarrays

Next Generation Cancer Diagnostics Market, By Application

• Biomarker Development
• CTC Analysis
• Proteomic Analysis
• Epigenetic Analysis
• Genetic Analysis

Next Generation Cancer Diagnostics Market, By Cancer Type

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Cervical Cancer
• Others

Next Generation Cancer Diagnostics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Next Generation Cancer Diagnostics Market.

Available Customizations:

Global Next Generation Cancer Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Next Generation Cancer Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Next-generation Sequencing, qPCR & Multiplexing, Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR), Protein Microarrays, DNA Microarrays)
  • 5.2.2. By Application (Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis)
  • 5.2.3. By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Next Generation Cancer Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Application
  • 6.2.3. By Cancer Type
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Next Generation Cancer Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Cancer Type
  • 6.3.2. Canada Next Generation Cancer Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Cancer Type
  • 6.3.3. Mexico Next Generation Cancer Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Cancer Type

7. Europe Next Generation Cancer Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Application
  • 7.2.3. By Cancer Type
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Next Generation Cancer Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Cancer Type
  • 7.3.2. France Next Generation Cancer Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Cancer Type
  • 7.3.3. United Kingdom Next Generation Cancer Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Cancer Type
  • 7.3.4. Italy Next Generation Cancer Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Cancer Type
  • 7.3.5. Spain Next Generation Cancer Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Cancer Type

8. Asia Pacific Next Generation Cancer Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Application
  • 8.2.3. By Cancer Type
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Next Generation Cancer Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Cancer Type
  • 8.3.2. India Next Generation Cancer Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Cancer Type
  • 8.3.3. Japan Next Generation Cancer Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Cancer Type
  • 8.3.4. South Korea Next Generation Cancer Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Cancer Type
  • 8.3.5. Australia Next Generation Cancer Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Cancer Type

9. Middle East & Africa Next Generation Cancer Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Application
  • 9.2.3. By Cancer Type
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Next Generation Cancer Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Cancer Type
  • 9.3.2. UAE Next Generation Cancer Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Cancer Type
  • 9.3.3. South Africa Next Generation Cancer Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Cancer Type

10. South America Next Generation Cancer Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Application
  • 10.2.3. By Cancer Type
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Next Generation Cancer Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Cancer Type
  • 10.3.2. Colombia Next Generation Cancer Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Cancer Type
  • 10.3.3. Argentina Next Generation Cancer Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Cancer Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Next Generation Cancer Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. GE HealthCare
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Janssen Pharmaceuticals, Inc.
• 15.3. Illumina, Inc.
• 15.4. Novartis AG
• 15.5. F. Hoffmann-La Roche Ltd
• 15.6. Koninklijke Philips N.V.
• 15.7. QIAGEN
• 15.8. Agilent Technologies, Inc.
• 15.9. Abbott Laboratories Inc.
• 15.10. Thermo Fisher Scientific Inc

16. Strategic Recommendations

17. About Us & Disclaimer